10.21147/j.issn.1000-9604.2022.03.07
National guidelines for diagnosis and treatment of prostate cancer 2022 in China(English version)
Contents
1.Overview
2.Etiology
2.1 Age and genetic factors
2.2 Exogenous factors
3.Pathological classification and grading system
3.1 Pathological grading and grouping of prostate cancer
3.2 Staging of prostate cancer
3.3 Risk grouping for patients with local or locally advanced prostate cancer
4.Diagnostic evaluation
4.1 Monitoring,screening and early diagnosis
4.2 Genetic testing
4.2.1 Providing genetic counseling and evaluating whether genetic testing is necessary
4.2.2 Treatment decision
4.3 Clinical diagnostic methods
4.3.1 DRE
4.3.2 MRI
4.3.3 Positron emission tomography-CT(PET-CT)
4.3.4 Prostate biopsy
5.Treatment of prostate cancer
5.1 Watchful waiting and active surveillance
5.2 Radical prostatectomy
5.2.1 Low-risk prostate cancer
5.2.2 Intermediate-risk prostate cancer
5.2.3 High-risk prostate cancer
5.2.4 Indications for nerve sparing surgery
5.2.5 PLND
5.2.6 Adjuvant therapy after radical prostatectomy
5.3 External radiotherapy
5.3.1 Indications for radical EBRT
5.3.2 Complications of EBRT for prostate cancer
5.3.3 Surgical treatment of biochemical recurrence after radiotherapy
5.3.4 Current situation and development of radiotherapy technology
national、prostate、english、cancer、china、diagnosis、guidelines、treatment、version
34
S;H313;G2
2022-08-09(万方平台首次上网日期,不代表论文的发表时间)
共19页
270-288